Cargando…

SARS-CoV-2 in immunocompromised individuals

Immunocompromised individuals and particularly those with hematologic malignancies are at increased risk for SARS-CoV-2-associated morbidity and mortality due to immunologic deficits that limit prevention, treatment, and clearance of the virus. Understanding the natural history of viral infections i...

Descripción completa

Detalles Bibliográficos
Autores principales:	DeWolf, Susan, Laracy, Justin C., Perales, Miguel-Angel, Kamboj, Mini, van den Brink, Marcel R.M., Vardhana, Santosha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Inc. 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468314/ https://www.ncbi.nlm.nih.gov/pubmed/36182669 http://dx.doi.org/10.1016/j.immuni.2022.09.006

Ejemplares similares

Discordant SARS-CoV-2 spike protein receptor binding domain IgG and neutralization after B-cell depletion
por: Noy, Ariela, et al.
Publicado: (2022)

Outcomes and Management of Sars-CoV2 Omicron Variant in Recipients of Hematopoietic Cell Transplantation (HCT) and CAR-T Therapy
por: Infante, Maria Stefania, et al.
Publicado: (2022)

Supported Planar Bilayers for the Formation of Study of Immunological Synapses and Kinapse
por: Vardhana, Santosha, et al.
Publicado: (2008)

Timing and Immune Status after Cellular Therapies Predict Response to COVID-19 Vaccines
por: Tamari, Roni, et al.
Publicado: (2021)

Concurrent Infection with SARS-CoV-2 and Pneumocystis jirovecii in Immunocompromised and Immunocompetent Individuals
por: Gioia, Francesca, et al.
Publicado: (2022)

The many faces of the anti-COVID immune response
por: Vardhana, Santosha A., et al.
Publicado: (2020)

Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer
por: Aydillo, Teresa, et al.
Publicado: (2020)

Predictors of SARS-CoV-2 Omicron breakthrough infection after receipt of AZD7442 (tixagevimab-cilgavimab) for pre-exposure prophylaxis among hematologic malignancy patients
por: Laracy, Justin C., et al.
Publicado: (2023)

SARS-CoV-2 vaccination in the immunocompromised host
por: Connolly, Caoilfhionn M., et al.
Publicado: (2022)

Time to SARS-CoV-2 PCR Clearance in Immunocompromising Conditions: Is Test-Based Removal From Isolation Necessary in Severely Immunocompromised Individuals?
por: Epstein, Rachel L, et al.
Publicado: (2021)

491. Persistence of SARS-CoV-2 Iinfection in Immunocompromised Children
por: Dolan, Susan, et al.
Publicado: (2021)

Impaired mitochondrial oxidative phosphorylation limits the self-renewal of T cells exposed to persistent antigen
por: Vardhana, Santosha A., et al.
Publicado: (2020)

The Humoral Immune Response To SARS-CoV-2 Infection And/or Immunization in Immunocompromised Versus Immunocompetent Individuals
por: Illes, Peter, et al.
Publicado: (2022)

Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals
por: Lederer, Katlyn, et al.
Publicado: (2022)

Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
por: Choi, Bina, et al.
Publicado: (2020)

Antigenic evolution of SARS-CoV-2 in immunocompromised hosts
por: Smith, Cameron A, et al.
Publicado: (2022)

Viral dynamics of SARS-CoV-2 in immunocompromised patients
por: Utzon, Andrea N., et al.
Publicado: (2023)

Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer
por: Avanzato, Victoria A., et al.
Publicado: (2020)

SARS-CoV-2-Specific T Cell Responses in Immunocompromised Individuals with Cancer, HIV or Solid Organ Transplants
por: Reeg, David B., et al.
Publicado: (2023)

Differential cellular and humoral immune responses in immunocompromised individuals following multiple SARS-CoV-2 vaccinations
por: Meredith, Rhys T., et al.
Publicado: (2023)

Clinical applications of palifermin: amelioration of oral mucositis and other potential indications
por: Vadhan-Raj, Saroj, et al.
Publicado: (2013)

Prolonged viral shedding of SARS-CoV-2 in an immunocompromised patient
por: Nakajima, Yukiko, et al.
Publicado: (2021)

Monitoring and managing SARS-CoV-2 evolution in immunocompromised populations
por: Li, Pengfei, et al.
Publicado: (2022)

SARS-CoV-2 Evolution and Immune Escape in Immunocompromised Patients
por: Scherer, Erin M., et al.
Publicado: (2022)

Persistence of clinically relevant levels of SARS-CoV2 envelope gene subgenomic RNAs in non-immunocompromised individuals
por: Davies, Merlin, et al.
Publicado: (2022)

The spike gene target failure (SGTF) genomic signature is highly accurate for the identification of Alpha and Omicron SARS-CoV-2 variants
por: McMillen, Tracy, et al.
Publicado: (2022)

SARS-CoV-2 Variants in Immunocompromised Patient Given Antibody Monotherapy
por: Truffot, Aurélie, et al.
Publicado: (2021)

Genomic Evolution of SARS-CoV-2 Virus in Immunocompromised Patient, Ireland
por: Lynch, Maureen, et al.
Publicado: (2021)

Paxlovid in patients who are immunocompromised and hospitalised with SARS-CoV-2 infection
por: Sun, Fangfang, et al.
Publicado: (2022)

T-Cell-Dominated Immune Response Resolves Protracted SARS-CoV-2 Infection in the Absence of Neutralizing Antibodies in an Immunocompromised Individual
por: Bunse, Till, et al.
Publicado: (2023)

Hepatitis E in immunocompromised individuals
por: Damiris, Konstantinos, et al.
Publicado: (2022)

Salivary IgG to SARS-CoV-2 indicates seroconversion and correlates to serum neutralization in mRNA-vaccinated immunocompromised individuals
por: Healy, Katie, et al.
Publicado: (2022)

Effectiveness and waning of protection with the BNT162b2 vaccine against the SARS-CoV-2 Delta variant in immunocompromised individuals
por: Szekanecz, Zoltán, et al.
Publicado: (2023)

Severe clinical relapse in an immunocompromised host with persistent SARS-CoV-2 infection
por: Reuken, Philipp A., et al.
Publicado: (2021)

SARS-CoV-2 late shedding may be infectious between immunocompromised hosts
por: Kaila, Ville, et al.
Publicado: (2021)

Secondary organising pneumonia to persistent SARS-CoV-2 infection in immunocompromised patient
por: Granados, Galo David, et al.
Publicado: (2022)

Sotrovimab drives SARS-CoV-2 omicron variant evolution in immunocompromised patients
por: Destras, Grégory, et al.
Publicado: (2022)

Protracted course of SARS-CoV-2 pneumonia in moderately to severely immunocompromised patients
por: Lee, Jeongjae, et al.
Publicado: (2023)

SARS-CoV-2 coinfection in immunocompromised host leads to the generation of recombinant strain
por: Zannoli, Silvia, et al.
Publicado: (2023)

Nirmatrelvir/ritonavir as a potential treatment for prolonged SARS-CoV-2 infection in immunocompromised patients
por: Catalán, Ignacio Pérez, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5orsfooah43dgqdfal3dno9vvp